Evidence map›Paper›PMID 26110817›Full record

ArticlePloS one2015

Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.

Takashi Azuma, Hirotaka Ishiuchi, Tomomi Inoyama, Yusuke Teranishi, Misato Yamaoka, Takaji Sato, Naoyuki Yamashita, Hiroaki Tanaka, Yoshiki Mino

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Takashi AzumaOsaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Hirotaka IshiuchiOsaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Tomomi InoyamaOsaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Yusuke TeranishiOsaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Misato YamaokaOsaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Takaji SatoOsaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Naoyuki YamashitaResearch Center for Environmental Quality Management, Kyoto University, Otsu, Shiga, Japan.
Hiroaki TanakaResearch Center for Environmental Quality Management, Kyoto University, Otsu, Shiga, Japan.
Yoshiki MinoOsaka University of Pharmaceutical Sciences, Takatsuki, Osaka, Japan.
Osaka University of Pharmaceutical Sciences · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is the first report of the detection of two new anti-influenza drugs, peramivir (PER) and laninamivir (LAN), in Japanese sewage effluent and river waters. Over about 1 year from October 2013 to July 2014, including the influenza prevalence season in January and February 2014, we monitored for five anti-influenza drugs-oseltamivir (OS), oseltamivir carboxylate (OC), zanamivir (ZAN), PER, and LAN-in river waters and in sewage effluent flowing into urban rivers of the Yodo River system in Japan. The dynamic profiles of these anti-influenza drugs were synchronized well with that of the numbers of influenza patients treated with the drugs. The highest levels in sewage effluents and river waters were, respectively, 82 and 41 ng/L (OS), 347 and 125 ng/L (OC), 110 and 35 ng/L (ZAN), 64 and 11 ng/L (PER), and 21 and 9 ng/L (LAN). However, application of ozone treatment before discharge from sewage treatment plants was effective in reducing the levels of these anti-influenza drugs in effluent. The effectiveness of the ozone treatment and the drug dependent difference in susceptibility against ozone were further evidenced by ozonation of a STP effluent in a batch reactor. These findings should help to promote further environmental risk assessment of the generation of drug-resistant influenza viruses in aquatic environments.

Indexed as

Acids, CarbocyclicAntiviral AgentsCitiesCyclopentanesDrug ResiduesEnvironmental MonitoringGuanidinesJapanLimit of DetectionOseltamivirOzonePyransRisk AssessmentRiversSewageSialic AcidsAcids, CarbocyclicAntiviral AgentsCyclopentanesGuanidineslaninamivirOseltamiviroseltamivir carboxylateOzoneperamivirPyransSewageSialic AcidsWater Pollutants, ChemicalZanamivir

Identifiers

PMID26110817
PMCPMC4482326
OpenAlexW770000062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.